Skip to content
Trial Eligibility
Menu

Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia

NCT02621944

This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

Hypoxic-Ischemic Encephalopathy (HIE) occurs in 20 per 1000 births. Only 47% of neonates treated with the state of the art therapy (induced systemic hypothermia) have normal outcomes. Therefore, other promising therapies that potentially work in synergy with hypothermia to improve neurologic outcomes need to be tested. One potential agent is melatonin. Melatonin is a naturally occurring substance produced mainly from the pineal gland. Melatonin is widely known for its role in regulating the circadian rhythm, but it has many other effects that may benefit infants with HI injury.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Hypoxic Ischemic Encephalopathy

Eligibility basics and study details

Study type
Interventional
Phase
Early Phase 1
Ages
Up to 6 Hours
Sex
All
Healthy volunteers
Not accepted
Sponsor
University of Florida
Last updated on ClinicalTrials.gov
June 29, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Florida · 2

  • University of Florida · Gainesville, FL
  • Florida Hospital for Children · Orlando, FL

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.